Cardiol Therapeutics shares positive new study results supporting lead drug’s ability to protect against heart failure

Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) announced positive results from a new study that highlighted its cannabidiol formulation’s ability to combat heart failure. The study found that Cardiol's cannabidiol formulation significantly reduced myocyte hypertrophy in a model of non-ischemic heart failure. Additional results showed a dose-dependent reduction of key inflammation markers, decreases in fibrosis, and lower B-type Natriuretic Peptide (BNP) expression, which is widely used to indicate the severity of heart failure. READ: Cardiol Therapeutics expecting significant growth in 2020 with launch of its pharmaceutical cannabidiol formulation in Canada Results indicate that Cardiol’s cannabidiol reduced the amount of BNP released, supporting its formulation as a cardioprotective therapy, the Toronto-based company told shareholders. Cardiol’s cannabidiol formulation, CardiolRx, is a pharmaceutically produced, THC-free (5ppm), highly concentrated product being developed to fight cardiac diseases. The positive data supports the firm’s plans for its Phase 2 trial looking at acute myocarditis, an inflammatory form of heart failure. The current study results support the anti-inflammatory and anti-fibrotic activity of Cardiol’s cannabidiol formulation when it comes to heart failure. Data submitted by its research collaborators was showcased at the American College of Cardiology's 69th Annual Scientific Session & Expo together with the World Congress of Cardiology, held virtually from March 28-30. "The data accepted for presentation at the ACC underscore the importance of Cardiol's research initiatives aimed at developing novel therapeutic strategies to address the devastating consequences of heart failure," stated David Elsley, Cardiol’s CEO. "The data also support our long-standing view concerning the powerful anti-inflammatory, anti-fibrotic, and cardioprotective properties of pharmaceutically produced cannabidiol, and serve as an encouraging scientific foundation for our planned international trial in acute myocarditis," he added. Cardiol plans to develop its cannabidiol formulation to treat chronic heart failure, a major healthcare burden in North America, costing the US healthcare system over US$30 billion a year. Contact Angela at angela@proactiveinvestors.com Follow her on Twitter @AHarmantas